— Know what they know.
Not Investment Advice
Also trades as: 0HD2.L (LSE) · $vol 0M · DUL.DE (XETRA) · $vol 0M

ALNY NASDAQ

Alnylam Pharmaceuticals, Inc.
1W: -1.7% 1M: -11.2% 3M: -20.9% YTD: -43.3% 1Y: -51.1% 3Y: +40.2% 5Y: +9.8%
$226.79
-0.87 (-0.38%)
 
Weekly Expected Move ±5.6%
$199 $211 $224 $237 $249
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 38 · $30.3B mcap · 133M float · 1.26% daily turnover · Short 40% of daily vol
Credit Risk of going bust: lower than 72% of companies Debt: 4.0% of company value Bonds: $81.8M held by 45 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.82 (down 99.6%), Alnylam Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $1.27B against a stock market value of $30.46B.
Distance to default 7.98 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $505.5M (short-term plus half of long-term), stock volatility 51.3%; Altman Z'' 1.62. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.

📊 Key Metrics

TTM
$5B
Revenue
+95.1% YoY
$808M
Net Income
+353.2% YoY
$543M
Free Cash Flow
+1141.6% YoY
76.9%
Gross Margin
17.9%
Op. Margin
12.7%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE100.7%
ROA16.0%
ROIC-152.8%

Valuation

P/E37.2
P/B22.3
EV/EBITDA34.4

Leverage

Debt/Equity0.94
Current Ratio3.05
Interest Cov.3.4x

Quality Scores

Piotroski F6/9
Altman Z6.53
Beneish M-1.73

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms